Figure 4
Arthritic TRPV1−/− mice show reduced mechanical hyperalgesia in the late phase. (A) Arthritis scores in TRPV1+/+, TRPV1+/− and TRPV1−/− mice. *p < 0.05, ##**P < 0.01, ###***p < 0.001: * TRPV1−/− or TRPV1+/− vs TRPV1+/+, #TRPV1+/− vs TRPV1−/− by two-way ANOVA. (B) Joint swelling at 0, 4, 8, 12 weeks in TRPV1−/− mice. (C,D) PWT measured at weekly intervals after the first CFA injection. Data are mean ± SEM of total tested mice (n = 7 for TRPV1+/+, n = 6 for TRPV1+/− and n = 7 for TRPV1−/− group). *p < 0.05, **P < 0.01, ***p < 0.001: TRPV1−/− vs TRPV1+/+ by two-way ANOVA. (E,F) qRT-PCR analysis of TDAG8 or ASIC3 gene expression in ipsilateral DRG at 12 weeks of TRPV1+/+ or TRPV1−/− mice, or at 0 weeks of TRPV1+/+ mice (ctrl). ***p < 0.001, TRPV1-/- vs TRPV1+/+; ###p < 0.001, TRPV1+/+ vs ctrl by one-way ANOVA. (G) Samples of ipsilateral joints at 4, 8, 12 weeks stained with hematoxylin and eosin are shown in (a-l). Data are mean ± SEM severity score for synovial inflammation (H), bone erosion (I), and cartilage damage (J). *p < 0.05, **P < 0.01, comparing TRPV1−/− vs WT by nonparametric Mann-Whitney U test.
